Deep Track, an investment firm, led a $158m Series B-2 round in TORL BioTherapeutics, a clinical-stage biotechnology company, with participation from RA Capital Management, Perceptive Advisors, Avidity Partners, Goldman Sachs Alternatives, UC Investments, Bristol Myers Squibb, Vertex Ventures HC, Moore Strategic Ventures, Blue Owl Healthcare Opportunities, and Perceptive Xontogeny Venture. "We are grateful for the continued support from our existing world-class life sciences investors and are extremely pleased to add RA Capital Management, Perceptive Advisors, and Avidity Partners to the TORL team. This investment significantly enhances our opportunity to deliver multiple data-driven milestones from our novel antibody-based discovery platform and clinical-stage oncology drug development pipeline," Mark Alles, TORL Chairman and CEO.